裡面醫生寫的理由跟FDA撤銷網頁的內容不一樣，網頁是說： Today, the FDA revoked the EUA that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients.
Based on its ongoing analysis of emerging scientific data, specifically the sustained increase of SARS-CoV-2 viral variants that are resistant to bamlanivimab alone resulting in the increased risk for treatment failure
although the FDA is now revoking this EUA, alternative monoclonal antibody therapies remain available under EUA, including REGEN-COV (casirivimab and imdevimab, administered together), and bamlanivimab and etesevimab, administered together
For now, the FDA recommends using Regeneron's antibody cocktail instead. 考慮實際上藥物審核是一家一家單獨過，台灣又老是喜歡用抄的，用抄的就要抄的新抄的快，現在要進抗體藥物，Regeneron's antibody cocktail應該是比較好的選擇。
Today, the FDA revoked the EUA that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients.
真的要搞清楚的是，人家強調對變種的治療效果會出問題，這個抗體對台灣的英國變種病毒株效力如何？
做重組蛋白疫苗的都要引以為鑑，同樣的狀況也可能發生……
考慮實際上藥物審核是一家一家單獨過，台灣又老是喜歡用抄的，用抄的就要抄的新抄的快，現在要進抗體藥物，Regeneron's antibody cocktail應該是比較好的選擇。